GleamWall
中文EN

ALVO Alvotech IFRS Annual reports only

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1898416 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY19.7%
TTM net income YoY112.0%
TTM EPS YoY111.5%
Revenue 3-yr CAGR91.9%
Net income 3-yr CAGR—

Margins

Gross margin59.8%
Operating margin13.3%
Net margin4.8%
FCF margin-19.6%
EBITDA margin19.8%

Returns

ROE—
ROA2.1%
ROIC (approx.)5.4%
Asset turnover0.43x

Leverage & solvency

Liabilities / assets119.1%
Debt / equity—
Current ratio1.89x
Interest coverage0.52x

Cash quality & payout

Operating cash flow / net income-1.80x
Accruals ratio5.8%
Payout ratio0.0%
Capex / revenue11.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue$586.32M$489.68M
Cost of revenue$235.56M$185.31M
Gross profit$350.76M$304.37M
R&D expense$184.19M$171.31M
SG&A expense$90.95M$65.71M
Operating income$78.21M$69.64M
Interest expense$149.19M$303.17M
Pretax income$136.35M-$217.56M
Income tax$108.43M$14.30M
Net income$27.92M-$231.86M
EBITDA$116.06M$100.94M
EPS (basic)0.10-0.87
EPS (diluted)0.10-0.87
Weighted avg. shares (diluted)291.34M267.92M
Balance sheet
Cash & equivalents$172.36M$51.43M
Receivables$69.74M$160.22M
Inventory$220.05M$127.89M
Current assets$574.01M$455.02M
PP&E, netmay include right-of-use assets (IFRS)$356.40M$284.55M
Goodwill$12.84M$11.33M
Intangibles$81.83M$20.62M
Total assets$1.49B$1.22B
Current liabilities$304.08M$193.40M
Short-term debt$36.92M$32.70M
Long-term debt$1.26B$1.04B
Total debt$1.30B$1.07B
Total liabilities$1.77B$1.63B
Shareholders' equity-$284.49M-$412.77M
Net debt$1.13B$1.02B
Shares outstanding312.02M301.81M
Cash flow statement
Operating cash flow-$50.20M-$236.84M
Capital expenditure$64.47M$53.66M
Free cash flow-$114.67M-$290.50M
Investing cash flow-$104.22M-$18.87M
Financing cash flow$270.83M$297.31M
Depreciation & amortization$37.85M$31.30M
Stock-based compensation$7.38M$7.63M
Dividends paid$0$0

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.